Scottish Health Minister Visits REPROCELL Japan to Strengthen Life Sciences Collaboration
02 July 2025
Scottish Health Minister Neil Gray visits REPROCELL Japan to enhance life sciences collaboration, highlighting strong ties and innovative healthcare advancements between Scotland and Japan.
PRESS RELEASE: REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)
08 February 2024
REPROCELL will soon add a third clinical pipeline, TIL therapy for cervical cancer, in addition to Stemchymal for spinocerebellar ataxia, and iPSC-derived neuroglial cells for ALS.
End of 2023 Newsletter
15 December 2023
Discover the latest advancements in stem cell and drug discovery research at REPROCELL. From GMP MSC production to Pharmacology-AI services, explore how REPROCELL is revolutionizing the field. Stay updated with their collaborations and partnerships for precision medicine and clinical capabilities.
REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study
24 October 2023
REPROCELL supports Silo Pharma research success, investigating the effects of SPU-21 Peptide on rheumatoid arthritis in a human synovial tissue study
Simplifying AI data analysis for scientists – as REPROCELL, IBM and STFC Hartree Centre successfully launch Pharmacology-AI platform
01 June 2023
REPROCELL has collaborated with HNCDI to create a machine learning (ML) platform that simplifies and accelerates the analysis of big data from drug development studies.
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
09 December 2022
The three-month study, conducted at REPROCELL, will assess the binding affinity of the peptide in healthy human and RA synovial tissue.
Building economic resilience and unleashing productivity through digital innovation
09 November 2022
CEO of REPROCELL said his company was among those that had received support from HNCDI to help it develop new approaches to drug development.
REPROCELL, IBM and STFC harness the power of AI in drug discovery and precision medicine
31 August 2022
Collaboration at Hartree NCDI combines REPROCELL’s tests of drug efficacy in human living tissues with IBM expertise in AI and machine learning.
Preclinical studies by REPROCELL give COPD drug a final boost before clinical trials
17 August 2022
Learn how scientists at REPROCELL compared the effects of RCD405 with drugs that are currently used to treat respiratory disease in human living bronchi.
Life science after lockdown: SPS returns for 2022
15 August 2022
Discover the first, in-person Saftey Pharmacology Society annual meeting since 2019: a dynamic forum, known for its global networking opportunities.
REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development
08 March 2022
Read how REPROCELL and IBM developed a novel Machine Learning driven precision medicine strategy for drug development.
REPROCELL spotlights the power of smarter biospecimens in new global publication
21 January 2022
REPROCELL has published an article highlighting the power of biospecimens in EBR. Visit the news section of our website to find out more.
Hoth Therapeutics Extends Partnership Agreement with REPROCELL
25 October 2021
Hoth Therapeutics has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in IBD. Find out why.
REPROCELL highlights the power of human fresh tissue in global publication
05 July 2021
This article explains the benefits of human fresh tissue testing in drug discovery, describing studies where these assays have helped clinical trials.
Hoth Therapeutics Executes Partnership Agreement with REPROCELL to Assess the Effect of HT-003 Therapeutic Platform on Inflammatory Bowel Disease
15 March 2021
Hoth Therapeutics has executed a partnership agreement with REPROCELL to assess the effect of its HT-003 therapeutic platform on tissue from IBD donors.
eTheRNA-led international consortium starts preclinical studies of cross-strain protective COVID-19 mRNA vaccine for high risk populations
16 July 2020
Learn more about how eTheRNA's mRNA covid vaccine, developed in partnership with REPROCELL, is designed to be protective against future viral variations.
Why eTheRNA's mRNA vaccine may offer a long-term solution to COVID
13 July 2020
Find out why eTheRNA's mRNA vaccine may offer a long-term solution to COVID in our interview with REPROCELL's CEO.
Patients with IBD absorb drugs differently from healthy individuals
16 January 2020
Read about how a recent study by researchers from REPROCELL found that IBD patients display different drug absorption profiles to healthy individuals.
REPROCELL can now predict oral bioavailability in fresh IBD tissue
14 January 2020
REPROCELL (Biopta) today announced that they can predict test article permeability using gastrointestinal resections from IBD donors.
Early understanding of pharmacology and genomics can improve precision medicine strategies
23 December 2019
REPROCELL announce the successful publication of a novel study in pharmacology and genomics to improve strategies for precision medicine.